Drug-Induced Linear IgA Bullous Dermatosis Associated with Ceftriaxone- and Metronidazole-Specific T Cells
Background: Previous reports indicate that various drugs may induce linear IgA bullous dermatosis (LABD). The role of T cells and T-cell-derived cytokines in the pathomechanism of such skin lesions, however, has remained unclear. Objective: To describe a case of LABD induced by ceftriaxone and metro...
Gespeichert in:
Veröffentlicht in: | Dermatology (Basel) 1999-01, Vol.199 (1), p.25-30 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 30 |
---|---|
container_issue | 1 |
container_start_page | 25 |
container_title | Dermatology (Basel) |
container_volume | 199 |
creator | Yawalkar, N. Reimers, A. Hari, Y. Hunziker, T. Gerber, H. Müller, U. Pichler, W. |
description | Background: Previous reports indicate that various drugs may induce linear IgA bullous dermatosis (LABD). The role of T cells and T-cell-derived cytokines in the pathomechanism of such skin lesions, however, has remained unclear. Objective: To describe a case of LABD induced by ceftriaxone and metronidazole in an 80-year-old female suffering from cholelithiasis with concomitant cholecystitis and provide evidence that drug-specific T cells and their cytokines may contribute to the development of LABD lesions. Methods: We performed flow cytometry analysis of peripheral blood T cells during LABD, epicutaneous testing (scratch-patch) and lymphocyte proliferation analysis (LTT) with the suspected drugs, routine histological and immunohistochemical examination of the acute skin lesions during LABD as well as of the positive epicutaneous test reactions and measurement of cytokines (IL-4, IL-5, IL-10, TNF-á, IFN-ã) in the supernatant of the LTT cultures. Results: An increased number mainly of activated CD8+ cells was detected in the peripheral blood during LABD. T cell sensitization to ceftriaxone and metronidazole was confirmed by epicutaneous testing and LTT, indicating that these methods may be useful in identifying the causative drugs. Enhanced cytokine levels, particularly of IL-5, were found in the supernatant of the LTT stimulated with ceftriaxone and metronidazole. Furthermore, in situ expression of IL-5 was confirmed in the patient’s skin lesions by immunohistochemistry. Conclusion: Our findings suggest that in addition to IgA antibodies drug-specific T cells and their subsequent release of cytokines may play an important role in the pathogenesis of drug-induced LABD. |
doi_str_mv | 10.1159/000018173 |
format | Article |
fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_18173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20929350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c415t-511face03d8fdaf19a26e2622c5e0c7424cb677c30fab35ce5392859813dc9ee3</originalsourceid><addsrcrecordid>eNpt0N1rFDEQAPBQLG2tffBZkFBE8GE1H5vd5PG8s_bgiqD1ecklkzPn3uaa7KL2r2-ue7RFmpeEmR8zk0HoNSUfKRXqE8mHSlrzA3RCS0YLJTl7kd85WsiqEsfoZUrrrJis1RE6pqQslRL8BK1ncVgV884OBixe-A50xPPVBH8e2jYMCc8gbnQfkk94klIwXvcZ_vH9LzwF10ev_4YOCqw7i6-gj6HzVt-GFoofWzDeeYOvs2zb9AodOt0mONvfp-jnxZfr6WWx-PZ1Pp0sClNS0ReCUqcNEG6ls9pRpVkFrGLMCCCmLllpllVdG06cXnJhQHDFpFCScmsUAD9F78e62xhuBkh9s_HJ5Al0B_lHDSOKKS5Ihuf_wXUYYpdna1gtSFVVcoc-jMjEkFIE12yj3-j4r6Gk2W2_edh-tm_3BYflBuwTOa47g3d7oJPRrYu6Mz49OqlqwXY934zst44riE_yY5fzZ7Oz71f3oNlax-8AogOfrQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>275066680</pqid></control><display><type>article</type><title>Drug-Induced Linear IgA Bullous Dermatosis Associated with Ceftriaxone- and Metronidazole-Specific T Cells</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Yawalkar, N. ; Reimers, A. ; Hari, Y. ; Hunziker, T. ; Gerber, H. ; Müller, U. ; Pichler, W.</creator><creatorcontrib>Yawalkar, N. ; Reimers, A. ; Hari, Y. ; Hunziker, T. ; Gerber, H. ; Müller, U. ; Pichler, W.</creatorcontrib><description>Background: Previous reports indicate that various drugs may induce linear IgA bullous dermatosis (LABD). The role of T cells and T-cell-derived cytokines in the pathomechanism of such skin lesions, however, has remained unclear. Objective: To describe a case of LABD induced by ceftriaxone and metronidazole in an 80-year-old female suffering from cholelithiasis with concomitant cholecystitis and provide evidence that drug-specific T cells and their cytokines may contribute to the development of LABD lesions. Methods: We performed flow cytometry analysis of peripheral blood T cells during LABD, epicutaneous testing (scratch-patch) and lymphocyte proliferation analysis (LTT) with the suspected drugs, routine histological and immunohistochemical examination of the acute skin lesions during LABD as well as of the positive epicutaneous test reactions and measurement of cytokines (IL-4, IL-5, IL-10, TNF-á, IFN-ã) in the supernatant of the LTT cultures. Results: An increased number mainly of activated CD8+ cells was detected in the peripheral blood during LABD. T cell sensitization to ceftriaxone and metronidazole was confirmed by epicutaneous testing and LTT, indicating that these methods may be useful in identifying the causative drugs. Enhanced cytokine levels, particularly of IL-5, were found in the supernatant of the LTT stimulated with ceftriaxone and metronidazole. Furthermore, in situ expression of IL-5 was confirmed in the patient’s skin lesions by immunohistochemistry. Conclusion: Our findings suggest that in addition to IgA antibodies drug-specific T cells and their subsequent release of cytokines may play an important role in the pathogenesis of drug-induced LABD.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000018173</identifier><identifier>PMID: 10449953</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Aged ; Aged, 80 and over ; Anti-Infective Agents - adverse effects ; Anti-Infective Agents - therapeutic use ; Biological and medical sciences ; CD8-Positive T-Lymphocytes - drug effects ; CD8-Positive T-Lymphocytes - metabolism ; Ceftriaxone - adverse effects ; Ceftriaxone - therapeutic use ; Cell Division - drug effects ; Clinical and Laboratory Investigations ; Drug toxicity and drugs side effects treatment ; Female ; Gallbladder Diseases - drug therapy ; HLA-DR Antigens - biosynthesis ; HLA-DR Antigens - drug effects ; Humans ; Immunoglobulin A - immunology ; Interferon-gamma - biosynthesis ; Interferon-gamma - drug effects ; Interleukin-5 - biosynthesis ; Medical sciences ; Metronidazole - adverse effects ; Metronidazole - therapeutic use ; Pharmacology. Drug treatments ; Skin - drug effects ; Skin - metabolism ; Skin - pathology ; Skin Diseases, Vesiculobullous - chemically induced ; Skin Diseases, Vesiculobullous - immunology ; Skin Diseases, Vesiculobullous - pathology ; Skin Tests ; T-Lymphocytes - cytology ; T-Lymphocytes - drug effects ; T-Lymphocytes - metabolism ; Toxicity: skin, dermoskeleton</subject><ispartof>Dermatology (Basel), 1999-01, Vol.199 (1), p.25-30</ispartof><rights>1999 S. Karger AG, Basel</rights><rights>1999 INIST-CNRS</rights><rights>Copyright (c) 1999 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c415t-511face03d8fdaf19a26e2622c5e0c7424cb677c30fab35ce5392859813dc9ee3</citedby><cites>FETCH-LOGICAL-c415t-511face03d8fdaf19a26e2622c5e0c7424cb677c30fab35ce5392859813dc9ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>309,310,314,780,784,789,790,2429,23930,23931,25140,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1897520$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10449953$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yawalkar, N.</creatorcontrib><creatorcontrib>Reimers, A.</creatorcontrib><creatorcontrib>Hari, Y.</creatorcontrib><creatorcontrib>Hunziker, T.</creatorcontrib><creatorcontrib>Gerber, H.</creatorcontrib><creatorcontrib>Müller, U.</creatorcontrib><creatorcontrib>Pichler, W.</creatorcontrib><title>Drug-Induced Linear IgA Bullous Dermatosis Associated with Ceftriaxone- and Metronidazole-Specific T Cells</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Background: Previous reports indicate that various drugs may induce linear IgA bullous dermatosis (LABD). The role of T cells and T-cell-derived cytokines in the pathomechanism of such skin lesions, however, has remained unclear. Objective: To describe a case of LABD induced by ceftriaxone and metronidazole in an 80-year-old female suffering from cholelithiasis with concomitant cholecystitis and provide evidence that drug-specific T cells and their cytokines may contribute to the development of LABD lesions. Methods: We performed flow cytometry analysis of peripheral blood T cells during LABD, epicutaneous testing (scratch-patch) and lymphocyte proliferation analysis (LTT) with the suspected drugs, routine histological and immunohistochemical examination of the acute skin lesions during LABD as well as of the positive epicutaneous test reactions and measurement of cytokines (IL-4, IL-5, IL-10, TNF-á, IFN-ã) in the supernatant of the LTT cultures. Results: An increased number mainly of activated CD8+ cells was detected in the peripheral blood during LABD. T cell sensitization to ceftriaxone and metronidazole was confirmed by epicutaneous testing and LTT, indicating that these methods may be useful in identifying the causative drugs. Enhanced cytokine levels, particularly of IL-5, were found in the supernatant of the LTT stimulated with ceftriaxone and metronidazole. Furthermore, in situ expression of IL-5 was confirmed in the patient’s skin lesions by immunohistochemistry. Conclusion: Our findings suggest that in addition to IgA antibodies drug-specific T cells and their subsequent release of cytokines may play an important role in the pathogenesis of drug-induced LABD.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Infective Agents - adverse effects</subject><subject>Anti-Infective Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CD8-Positive T-Lymphocytes - drug effects</subject><subject>CD8-Positive T-Lymphocytes - metabolism</subject><subject>Ceftriaxone - adverse effects</subject><subject>Ceftriaxone - therapeutic use</subject><subject>Cell Division - drug effects</subject><subject>Clinical and Laboratory Investigations</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Gallbladder Diseases - drug therapy</subject><subject>HLA-DR Antigens - biosynthesis</subject><subject>HLA-DR Antigens - drug effects</subject><subject>Humans</subject><subject>Immunoglobulin A - immunology</subject><subject>Interferon-gamma - biosynthesis</subject><subject>Interferon-gamma - drug effects</subject><subject>Interleukin-5 - biosynthesis</subject><subject>Medical sciences</subject><subject>Metronidazole - adverse effects</subject><subject>Metronidazole - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Skin - drug effects</subject><subject>Skin - metabolism</subject><subject>Skin - pathology</subject><subject>Skin Diseases, Vesiculobullous - chemically induced</subject><subject>Skin Diseases, Vesiculobullous - immunology</subject><subject>Skin Diseases, Vesiculobullous - pathology</subject><subject>Skin Tests</subject><subject>T-Lymphocytes - cytology</subject><subject>T-Lymphocytes - drug effects</subject><subject>T-Lymphocytes - metabolism</subject><subject>Toxicity: skin, dermoskeleton</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0N1rFDEQAPBQLG2tffBZkFBE8GE1H5vd5PG8s_bgiqD1ecklkzPn3uaa7KL2r2-ue7RFmpeEmR8zk0HoNSUfKRXqE8mHSlrzA3RCS0YLJTl7kd85WsiqEsfoZUrrrJis1RE6pqQslRL8BK1ncVgV884OBixe-A50xPPVBH8e2jYMCc8gbnQfkk94klIwXvcZ_vH9LzwF10ev_4YOCqw7i6-gj6HzVt-GFoofWzDeeYOvs2zb9AodOt0mONvfp-jnxZfr6WWx-PZ1Pp0sClNS0ReCUqcNEG6ls9pRpVkFrGLMCCCmLllpllVdG06cXnJhQHDFpFCScmsUAD9F78e62xhuBkh9s_HJ5Al0B_lHDSOKKS5Ihuf_wXUYYpdna1gtSFVVcoc-jMjEkFIE12yj3-j4r6Gk2W2_edh-tm_3BYflBuwTOa47g3d7oJPRrYu6Mz49OqlqwXY934zst44riE_yY5fzZ7Oz71f3oNlax-8AogOfrQ</recordid><startdate>19990101</startdate><enddate>19990101</enddate><creator>Yawalkar, N.</creator><creator>Reimers, A.</creator><creator>Hari, Y.</creator><creator>Hunziker, T.</creator><creator>Gerber, H.</creator><creator>Müller, U.</creator><creator>Pichler, W.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>19990101</creationdate><title>Drug-Induced Linear IgA Bullous Dermatosis Associated with Ceftriaxone- and Metronidazole-Specific T Cells</title><author>Yawalkar, N. ; Reimers, A. ; Hari, Y. ; Hunziker, T. ; Gerber, H. ; Müller, U. ; Pichler, W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c415t-511face03d8fdaf19a26e2622c5e0c7424cb677c30fab35ce5392859813dc9ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Infective Agents - adverse effects</topic><topic>Anti-Infective Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CD8-Positive T-Lymphocytes - drug effects</topic><topic>CD8-Positive T-Lymphocytes - metabolism</topic><topic>Ceftriaxone - adverse effects</topic><topic>Ceftriaxone - therapeutic use</topic><topic>Cell Division - drug effects</topic><topic>Clinical and Laboratory Investigations</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Gallbladder Diseases - drug therapy</topic><topic>HLA-DR Antigens - biosynthesis</topic><topic>HLA-DR Antigens - drug effects</topic><topic>Humans</topic><topic>Immunoglobulin A - immunology</topic><topic>Interferon-gamma - biosynthesis</topic><topic>Interferon-gamma - drug effects</topic><topic>Interleukin-5 - biosynthesis</topic><topic>Medical sciences</topic><topic>Metronidazole - adverse effects</topic><topic>Metronidazole - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Skin - drug effects</topic><topic>Skin - metabolism</topic><topic>Skin - pathology</topic><topic>Skin Diseases, Vesiculobullous - chemically induced</topic><topic>Skin Diseases, Vesiculobullous - immunology</topic><topic>Skin Diseases, Vesiculobullous - pathology</topic><topic>Skin Tests</topic><topic>T-Lymphocytes - cytology</topic><topic>T-Lymphocytes - drug effects</topic><topic>T-Lymphocytes - metabolism</topic><topic>Toxicity: skin, dermoskeleton</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yawalkar, N.</creatorcontrib><creatorcontrib>Reimers, A.</creatorcontrib><creatorcontrib>Hari, Y.</creatorcontrib><creatorcontrib>Hunziker, T.</creatorcontrib><creatorcontrib>Gerber, H.</creatorcontrib><creatorcontrib>Müller, U.</creatorcontrib><creatorcontrib>Pichler, W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yawalkar, N.</au><au>Reimers, A.</au><au>Hari, Y.</au><au>Hunziker, T.</au><au>Gerber, H.</au><au>Müller, U.</au><au>Pichler, W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug-Induced Linear IgA Bullous Dermatosis Associated with Ceftriaxone- and Metronidazole-Specific T Cells</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>1999-01-01</date><risdate>1999</risdate><volume>199</volume><issue>1</issue><spage>25</spage><epage>30</epage><pages>25-30</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Background: Previous reports indicate that various drugs may induce linear IgA bullous dermatosis (LABD). The role of T cells and T-cell-derived cytokines in the pathomechanism of such skin lesions, however, has remained unclear. Objective: To describe a case of LABD induced by ceftriaxone and metronidazole in an 80-year-old female suffering from cholelithiasis with concomitant cholecystitis and provide evidence that drug-specific T cells and their cytokines may contribute to the development of LABD lesions. Methods: We performed flow cytometry analysis of peripheral blood T cells during LABD, epicutaneous testing (scratch-patch) and lymphocyte proliferation analysis (LTT) with the suspected drugs, routine histological and immunohistochemical examination of the acute skin lesions during LABD as well as of the positive epicutaneous test reactions and measurement of cytokines (IL-4, IL-5, IL-10, TNF-á, IFN-ã) in the supernatant of the LTT cultures. Results: An increased number mainly of activated CD8+ cells was detected in the peripheral blood during LABD. T cell sensitization to ceftriaxone and metronidazole was confirmed by epicutaneous testing and LTT, indicating that these methods may be useful in identifying the causative drugs. Enhanced cytokine levels, particularly of IL-5, were found in the supernatant of the LTT stimulated with ceftriaxone and metronidazole. Furthermore, in situ expression of IL-5 was confirmed in the patient’s skin lesions by immunohistochemistry. Conclusion: Our findings suggest that in addition to IgA antibodies drug-specific T cells and their subsequent release of cytokines may play an important role in the pathogenesis of drug-induced LABD.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>10449953</pmid><doi>10.1159/000018173</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1018-8665 |
ispartof | Dermatology (Basel), 1999-01, Vol.199 (1), p.25-30 |
issn | 1018-8665 1421-9832 |
language | eng |
recordid | cdi_karger_primary_18173 |
source | MEDLINE; Karger Journals Complete |
subjects | Aged Aged, 80 and over Anti-Infective Agents - adverse effects Anti-Infective Agents - therapeutic use Biological and medical sciences CD8-Positive T-Lymphocytes - drug effects CD8-Positive T-Lymphocytes - metabolism Ceftriaxone - adverse effects Ceftriaxone - therapeutic use Cell Division - drug effects Clinical and Laboratory Investigations Drug toxicity and drugs side effects treatment Female Gallbladder Diseases - drug therapy HLA-DR Antigens - biosynthesis HLA-DR Antigens - drug effects Humans Immunoglobulin A - immunology Interferon-gamma - biosynthesis Interferon-gamma - drug effects Interleukin-5 - biosynthesis Medical sciences Metronidazole - adverse effects Metronidazole - therapeutic use Pharmacology. Drug treatments Skin - drug effects Skin - metabolism Skin - pathology Skin Diseases, Vesiculobullous - chemically induced Skin Diseases, Vesiculobullous - immunology Skin Diseases, Vesiculobullous - pathology Skin Tests T-Lymphocytes - cytology T-Lymphocytes - drug effects T-Lymphocytes - metabolism Toxicity: skin, dermoskeleton |
title | Drug-Induced Linear IgA Bullous Dermatosis Associated with Ceftriaxone- and Metronidazole-Specific T Cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T19%3A53%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug-Induced%20Linear%20IgA%20Bullous%20Dermatosis%20Associated%20with%20Ceftriaxone-%20and%20Metronidazole-Specific%20T%20Cells&rft.jtitle=Dermatology%20(Basel)&rft.au=Yawalkar,%20N.&rft.date=1999-01-01&rft.volume=199&rft.issue=1&rft.spage=25&rft.epage=30&rft.pages=25-30&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000018173&rft_dat=%3Cproquest_karge%3E20929350%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=275066680&rft_id=info:pmid/10449953&rfr_iscdi=true |